China, trials started for a vaccine against Omicron

Sinopharm has launched trials for a specific vaccine against the Omicron variant, responsible for the most serious wave of infections in China since the Wuhan Covid-19 outbreak in early 2020, causing lockdowns for millions of people and paralyzing production in many areas of the country . The trial was launched in the inner province of Hunan and involves over four thousand participants, according to what was announced by the giant of the Chinese pharmaceutical sector, in a note quoted by the China Daily newspaper.
The state-owned Sinopharm group has produced one of the vaccines used in the vaccination campaign implemented by Beijing, which has crossed the milestone of 1.2 billion people fully vaccinated against Covid-19 (almost 90% of the 1,411 billion Chinese) , and has exceeded 3.3 billion doses administered. The vaccine was developed by a team of researchers from the China National Biotech Group (Cnbg), a subsidiary of Sinopharm, and according to Zhang Yuntao, vice president of Cnbg, it will take at least three to four months to complete the trial phase.